Ipamorelin
Symbol Ip · MW 712 Da
Selective GH secretagogue with minimal effect on cortisol or prolactin.
- Discovered
- 1998
- Half-life
- 2 hours
- Approval
- Not FDA-approved
Quick facts
- Category
- Hormone
- Route
- Injectable
- Molecular weight
- 712 Da
- Half-life
- 2 hours
- Discovered
- 1998
- Approval status
- Not FDA-approved
Reported effects
- Lean muscle support
- Improved sleep
- Fat metabolism
Overview
Ipamorelin is a selective growth hormone secretagogue known for stimulating natural GH release with fewer appetite-related effects compared with older peptides like GHRP-6. It is commonly associated with recovery, sleep quality, body composition, lean muscle support, and age-related hormone optimization. Ipamorelin is often considered one of the gentler GH peptides because it is designed to have less impact on cortisol and prolactin. Its purpose is to support the growth hormone axis while maintaining a more targeted hormone-signaling profile. As a hormone peptide, Ipamorelin is one of the most widely discussed options for natural GH stimulation.
Evidence context
Ipamorelin evidence summary
Human clinical evidence
Ipamorelin has an approval context listed in the Peptidic database. Approved use still depends on the specific indication, formulation, labeling, and clinician guidance.
Animal, preclinical, or formulation evidence
Ipamorelin may be discussed in animal, preclinical, in vitro, or early-stage research contexts. Those evidence types are useful for orientation but should not be treated as equivalent to approved human indications.
Status and evidence strength
Peptidic lists the approval status for Ipamorelin as Not FDA-approved. The reported effects below are reference fields from the peptide database, not medical promises. Source links are included later on the page when available so readers can continue review from primary or reputable sources.
How it's taken
- Typical Administration
- Injectable
- Typical Dosage
- No established approved dosage; commonly referenced range is 100–300 mcg per injection
- Typical Frequency
- 1–3 times daily
Dosing depends on the approved indication, formulation, titration schedule, and clinician guidance. This page is educational and not a substitute for medical advice.
Research sources
Source links included from peer-reviewed literature, clinical records, and medical databases for educational research context on Ipamorelin.
Internal links
Related peptides
Frequently asked questions
What category is Ipamorelin in?
Ipamorelin is listed in the Hormone category on Peptidic.
What route is Ipamorelin associated with?
Ipamorelin is associated with the injectable route in the Peptidic database. This is descriptive route context, not a use instruction.
Is Ipamorelin approved?
Peptidic lists the approval status for Ipamorelin as: Not FDA-approved. Approval details can vary by indication and jurisdiction.
Interested in Ipamorelin?
Enter your email and we'll send our recommended peptide vendor for educational research reference.
Review the peptide vendor research checklistEducational reference only · No spam · Unsubscribe anytime
For educational purposes only. Many peptides shown are research compounds and not approved for human use in all jurisdictions. Explore the full peptide database, peptide calculator, or peptide tracker.
Last reviewed for educational accuracy: 2026-06-01